Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?

July 6, 2024

Wockhardt’s Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk’s Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.

More To Explore

Mazagon Dock shares dive 13% as govt to exercises oversubscription option to sell additional 1.18% stake

Mazagon Dock OFS: Mazagon Dock Shipbuilders shares plunged 13% to hit an intraday low of ₹2,207.30 on the BSE on Monday, following the government’s decision

April 7, 2025

Fund Manager Talk | Long-term investors shouldn’t ghost small, midcaps: Gaurav Misra

In aggregate the valuations for the midcap are not too far away from long period averages while small caps are still away from their own

April 7, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003